Literature DB >> 33121339

Single-cell analysis of copy-number alterations in serous ovarian cancer reveals substantial heterogeneity in both low- and high-grade tumors.

Manonmani Kumar1, Robert R Bowers1, Joe R Delaney1.   

Abstract

Unusually high aneuploidy is a hallmark of epithelial serous ovarian cancer (SOC). Previous analyses have focused on aneuploidy on average across all tumor cells. With the expansion of single-cell sequencing technologies, however, an analysis of copy number heterogeneity cell-to-cell is now technically feasible. Here, we describe an analysis of single-cell RNA sequencing (scRNA-seq) data to infer arm-level aneuploidy in individual serous ovarian cancer cells. By first clustering high-quality sequenced epithelial versus non-epithelial cells, high-confidence tumor cell populations were identified. InferCNV was used to predict segmented copy-number alterations (CNAs), which were then used to determine arm-level aneuploidy at the single-cell level. Control comparisons of normal cells to normal cells showed zero arm-level aneuploidy, whereas a median of four aneuploid events were detectable in cancer cells. A heterogeneity analysis of high-grade tumor cells compared to low-grade tumor cells showed similar levels of cell-to-cell variation between cancer grades. Metastatic tumors potentially showed selection pressure with reduced cell-to-cell variation compared to cells from primary tumors. Minor cell populations with CNAs similar to metastatic cells were identified within the matched primary tumors. Taken together, these results provide a minimum estimate for single-cell aneuploidy in serous ovarian cancer and demonstrate the utility of single-cell sequencing for CNA analysis.

Entities:  

Keywords:  CNA; copy-number alterations; ovarian cancer; scRNA-seq; tumor heterogeneity

Mesh:

Year:  2020        PMID: 33121339      PMCID: PMC7714496          DOI: 10.1080/15384101.2020.1836439

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  53 in total

1.  Comprehensive Integration of Single-Cell Data.

Authors:  Tim Stuart; Andrew Butler; Paul Hoffman; Christoph Hafemeister; Efthymia Papalexi; William M Mauck; Yuhan Hao; Marlon Stoeckius; Peter Smibert; Rahul Satija
Journal:  Cell       Date:  2019-06-06       Impact factor: 41.582

2.  Genomic basis for RNA alterations in cancer.

Authors:  Claudia Calabrese; Natalie R Davidson; Deniz Demircioğlu; Nuno A Fonseca; Yao He; André Kahles; Kjong-Van Lehmann; Fenglin Liu; Yuichi Shiraishi; Cameron M Soulette; Lara Urban; Liliana Greger; Siliang Li; Dongbing Liu; Marc D Perry; Qian Xiang; Fan Zhang; Junjun Zhang; Peter Bailey; Serap Erkek; Katherine A Hoadley; Yong Hou; Matthew R Huska; Helena Kilpinen; Jan O Korbel; Maximillian G Marin; Julia Markowski; Tannistha Nandi; Qiang Pan-Hammarström; Chandra Sekhar Pedamallu; Reiner Siebert; Stefan G Stark; Hong Su; Patrick Tan; Sebastian M Waszak; Christina Yung; Shida Zhu; Philip Awadalla; Chad J Creighton; Matthew Meyerson; B F Francis Ouellette; Kui Wu; Huanming Yang; Alvis Brazma; Angela N Brooks; Jonathan Göke; Gunnar Rätsch; Roland F Schwarz; Oliver Stegle; Zemin Zhang
Journal:  Nature       Date:  2020-02-05       Impact factor: 49.962

3.  Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.

Authors:  Isabelle Ray-Coquard; Patricia Pautier; Sandro Pignata; David Pérol; Antonio González-Martín; Regina Berger; Keiichi Fujiwara; Ignace Vergote; Nicoletta Colombo; Johanna Mäenpää; Frédéric Selle; Jalid Sehouli; Domenica Lorusso; Eva M Guerra Alía; Alexander Reinthaller; Shoji Nagao; Claudia Lefeuvre-Plesse; Ulrich Canzler; Giovanni Scambia; Alain Lortholary; Frederik Marmé; Pierre Combe; Nikolaus de Gregorio; Manuel Rodrigues; Paul Buderath; Coraline Dubot; Alexander Burges; Benoît You; Eric Pujade-Lauraine; Philipp Harter
Journal:  N Engl J Med       Date:  2019-12-19       Impact factor: 91.245

Review 4.  FAK in cancer: mechanistic findings and clinical applications.

Authors:  Florian J Sulzmaier; Christine Jean; David D Schlaepfer
Journal:  Nat Rev Cancer       Date:  2014-08-07       Impact factor: 60.716

5.  Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

Authors:  Robert L Coleman; Gini F Fleming; Mark F Brady; Elizabeth M Swisher; Karina D Steffensen; Michael Friedlander; Aikou Okamoto; Kathleen N Moore; Noa Efrat Ben-Baruch; Theresa L Werner; Noelle G Cloven; Ana Oaknin; Paul A DiSilvestro; Mark A Morgan; Joo-Hyun Nam; Charles A Leath; Shibani Nicum; Andrea R Hagemann; Ramey D Littell; David Cella; Sally Baron-Hay; Jesus Garcia-Donas; Mika Mizuno; Katherine Bell-McGuinn; Danielle M Sullivan; Bruce A Bach; Sudipta Bhattacharya; Christine K Ratajczak; Peter J Ansell; Minh H Dinh; Carol Aghajanian; Michael A Bookman
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

6.  Identification of aneuploidy-selective antiproliferation compounds.

Authors:  Yun-Chi Tang; Bret R Williams; Jake J Siegel; Angelika Amon
Journal:  Cell       Date:  2011-02-18       Impact factor: 41.582

7.  Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.

Authors:  David A Engler; Sumeet Gupta; Whitfield B Growdon; Ronny I Drapkin; Mai Nitta; Petra A Sergent; Serena F Allred; Jenny Gross; Michael T Deavers; Wen-Lin Kuo; Beth Y Karlan; Bo R Rueda; Sandra Orsulic; David M Gershenson; Michael J Birrer; Joe W Gray; Gayatry Mohapatra
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240

8.  Whole Genome Pathway Analysis Identifies an Association of Cadmium Response Gene Loss with Copy Number Variation in Mutant p53 Bearing Uterine Endometrial Carcinomas.

Authors:  Joe Ryan Delaney; Dwayne G Stupack
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

9.  The temporal dynamics of chromosome instability in ovarian cancer cell lines and primary patient samples.

Authors:  Signe Penner-Goeke; Zelda Lichtensztejn; Megan Neufeld; Jennifer L Ali; Alon D Altman; Mark W Nachtigal; Kirk J McManus
Journal:  PLoS Genet       Date:  2017-04-04       Impact factor: 5.917

10.  A strategy to combine pathway-targeted low toxicity drugs in ovarian cancer.

Authors:  Joe R Delaney; Chandni Patel; Katelyn E McCabe; Dan Lu; Mitzie-Ann Davis; Isabelle Tancioni; Tami von Schalscha; Alena Bartakova; Carley Haft; David D Schlaepfer; Dwayne G Stupack
Journal:  Oncotarget       Date:  2015-10-13
View more
  4 in total

1.  Combination of Autophagy Selective Therapeutics With Doxil: An Assessment of Pathological Toxicity.

Authors:  Kristi L Helke; Radhika R Gudi; Chenthamarakshan Vasu; Joe R Delaney
Journal:  Front Toxicol       Date:  2022-06-29

2.  Autophagy modulating therapeutics inhibit ovarian cancer colony generation by polyploid giant cancer cells (PGCCs).

Authors:  Robert R Bowers; Maya F Andrade; Christian M Jones; Shai White-Gilbertson; Christina Voelkel-Johnson; Joe R Delaney
Journal:  BMC Cancer       Date:  2022-04-14       Impact factor: 4.638

3.  SWAN pathway-network identification of common aneuploidy-based oncogenic drivers.

Authors:  Robert R Bowers; Christian M Jones; Edwin A Paz; John K Barrows; Kent E Armeson; David T Long; Joe R Delaney
Journal:  Nucleic Acids Res       Date:  2022-04-22       Impact factor: 19.160

4.  Aneuploidy: An Opportunity Within Single-Cell RNA Sequencing Analysis.

Authors:  Joe R Delaney
Journal:  Biocell       Date:  2021       Impact factor: 1.110

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.